Sarah St. Clair
Chief Strategy Officer
BioAnalysis, LLC
This startup operates a non-clinical Contract Research Organization (CRO) specializing in biophysics and mass spectrometry for gene therapy and biotherapeutics. By providing scientifically rigorous analyses of monoclonal antibodies, therapeutic proteins, antibody-drug conjugates, and nanoparticles, the company delivers precise insights that enhance the development of these complex therapeutic candidates.
- Data & Analytics
- Biotechnology
- Healthcare Technology
Updated 6 months ago
Funding
Raised to date
$4.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
The development of gene therapies and biotherapeutics requires rigorous analytical testing to ensure product quality, safety, and efficacy. Traditional contract research organizations (CROs) may suffer from poor data quality and long turnaround times, hindering timely decision-making and slowing down the drug development process.
Solution
BioAnalysis is a non-clinical collaborative research organization (CRO) specializing in biophysics and mass spectrometry, providing high-quality analytical services for gene therapy, biotherapeutics, and the broader life science industries. The company offers comprehensive GMP and non-GMP testing services, including analytical ultracentrifugation (AUC), liquid chromatography-mass spectrometry (LCMS), high-performance liquid chromatography (HPLC), and dynamic light scattering (DLS). BioAnalysis focuses on delivering accurate data and analyses with industry-leading turnaround times, enabling clients to accelerate drug development from discovery to commercialization. Their commitment to client engagement and scientific expertise ensures that clients receive tailored solutions and support throughout the entire process.
Target Audience
BioAnalysis serves gene therapy and biotherapeutic companies, as well as other life science organizations, requiring analytical testing services to support drug development, manufacturing, and quality control.
Features
- Analytical Ultracentrifugation (AUC) for determining gene therapy vector incorporation, detecting aggregates, and assessing size distribution of lipid nanoparticles and monoclonal antibodies.
- Liquid Chromatography-Mass Spectrometry (LCMS) for protein identification, post-translational modification (PTM) analysis, peptide mapping, intact mass assessment, and host cell protein (HCP) analysis.
- High-Performance Liquid Chromatography (HPLC) for characterization, identification, and quantification of drug products and excipients, as well as purity and impurity testing.
- Dynamic Light Scattering (DLS) for aggregation and particle size determination.
- GMP-compliant assays for AUC, HPLC, DLS, and LCMS technologies.
- Capabilities for analyzing therapeutic mRNAs, guide RNAs, lipid nanoparticles (LNPs), and vaccines.
- Expertise in Size Exclusion Chromatography (SEC), Reverse Phase (RP), Ion Exchange (IEX), and Hydrophilic Interaction (HILIC).